Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

NMRA-215Positive

AI Analysis

Summary

Neumora Therapeutics reports favorable toxicology results for NMRA-215 and plans to submit an IND application in Q4 2026 with Phase 1 study initiation by end of 2026.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Favorable toxicology results reported; IND submission planned Q4 2026

Importance:5/10

Sentiment:

0.60

toxicologyIND filingPhase 1clinical advancement

Read the original article

Published by GlobeNewswire Clinical Studies on July 27, 2026 11:00 AM

Read Original